Experienced growth investor and operator focused on technology and healthcare companies across venture and growth-equity stages. Mathieu Boisvert brings a blend of operating experience and investment leadership, sourcing cross-border SaaS and life-science opportunities, leading due diligence, and serving on boards to drive commercial scaling and exit preparation. Capital focus spans Series B to growth transactions with emphasis on revenue traction, unit economics and operational playbooks.
Experienced growth investor and operator focused on technology and healthcare companies across venture and growth-equity stages. Mathieu Boisvert brings a blend of operating experience and investment leadership, sourcing cross-border SaaS and life-science opportunities, leading due diligence, and serving on boards to drive commercial scaling and exit preparation. Capital focus spans Series B to growth transactions with emphasis on revenue traction, unit economics and operational playbooks.
Blends growth-equity discipline with operator-led value creation, backing later-stage SaaS and life‑science companies showing clear revenue traction and repeatable unit economics. Emphasizes cross-border opportunities, rigorous commercial due diligence, and hands-on board engagement to refine GTM, metrics-driven scaling and exit readiness. Capital allocation favors Series B–growth rounds with staged support tied to operational milestones, conservative downside protections, and multi-year, growth-to-exit time horizons.
Blends growth-equity discipline with operator-led value creation, backing later-stage SaaS and life‑science companies showing clear revenue traction and repeatable unit economics. Emphasizes cross-border opportunities, rigorous commercial due diligence, and hands-on board engagement to refine GTM, metrics-driven scaling and exit readiness. Capital allocation favors Series B–growth rounds with staged support tied to operational milestones, conservative downside protections, and multi-year, growth-to-exit time horizons.
| Trades 301 | Longs Won 118/301 39% | Profit Factor 4.34 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.57M |
| Average Win $1.07M | Best Trade (Jul 10) $23.84M | Sharpe Ratio -9.4 |
| Average Loss -$158,352.25 | Worst Trade (Mar 31) -$2.66M | Z-Score -1.94 (97.36%) |
| Commissions $0 | Avg. Trade Length 4m 3w 6d | Expectancy $321,355.89 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 2,584 | 2,326 | 2,067 | 1,809 | 1,550 | 1,292 | 1,034 | 775 | 517 | 258 |